NEW DELHI – India's drug pricing regulator has withdrawn a series of guidelines that capped prices of diabetes, cardiovascular disease and asthma drugs. The sudden U-turn in policy was timed ahead of a recent visit by Indian Prime Minister Narendra Modi to the U.S. and has sharply divided the pharmaceutical industry that welcomes the move and public health analysts that oppose it.